Marcella Baldewijns

Marcella Baldewijns

Auto-generated profile, based on publicly available information

Marcella Baldewijns

Pathology, University Hospitals Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EOEline Oeyen
Eline Oeyen
LHLucien Hoekx
Lucien Hoekx
SWStefan De Wachter
Stefan De Wachter
MBMarcella Baldewijns
Marcella Baldewijns
FAFilip Ameye
Filip Ameye
IMInge Mertens
Inge Mertens
Diagnostic methods currently used for bladder cancer are cystoscopy and urine cytology. Cystoscopy is an invasive tool and has low sensitivity for carcinoma in situ. Urine cytology is non-invasive, is a low-cost method, and has a high specificity but low sensitivity for low-grade urothelial tumors. Despite the search for urinary biomarkers for the early and non-invasive detection of bladder cancer, no biomarkers are used at the present in daily clinical practice. Extracellular vesicles (EVs) have been recently studied as a promising source of biomarkers because of their role in intercellular communication and tumor progression. In this review, we give an overview of Food and Drug Administration (FDA)-approved urine tests to detect bladder cancer and why their use is not widespread in clinical practice. We also include non-FDA approved urinary biomarkers in this review. We describe the role of EVs in bladder cancer and their possible role as biomarkers for the diagnosis and follow-up of bladder cancer patients. We review recently discovered EV-derived biomarkers for the diagnosis of bladder cancer.

21 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LKLisa Kinget
Lisa Kinget
EREduard Roussel
Eduard Roussel
AVAnnelies Verbiest
Annelies Verbiest
MAMaarten Albersen
Maarten Albersen
Cristina Rodriguez-AntonaCristina Rodriguez-Antona
Cristina Rodriguez-Antona
BBBenoit Beuselinck
Benoit Beuselinck
Metastatic clear-cell renal cell carcinoma (m-ccRCC) is characterized by increased hypoxia-induced factor (HIF)-2α and vascular endothelial growth factor receptor (VEGFR)-dependent angiogenesis through loss of function of the von Hippel–Lindau protein. VEGFR tyrosine kinase inhibitors (VEGFR-TKIs) are a cornerstone of m-ccRCC treatment, and new treatments targeting HIF-2α are currently under investigation. However, predictive biomarkers for these treatments are lacking. In this retrospective cohort study including 109 patients treated with VEGFR-targeted therapies as first-line treatment, we aimed to study the possible predictive function of microRNAs (miRNAs) targeting HIF-2α, VEGFR1 and VEGFR2. We selected miRNAs inversely correlated with HIF-2α, VEGFR1 and/or VEGFR2 expression and with predicted target sites in the respective genes and subsequently studied their impact on therapeutic outcomes. We identified four miRNAs (miR-34c-5p, miR-221-3p, miR-222-3p and miR-3529-3p) inversely correlated with VEGFR1 and/or VEGFR2 expression and associated with tumor shrinkage and progression-free survival (PFS) upon treatment with VEGFR-TKIs, highlighting the potential predictive value of these miRNAs. Moreover, we identified three miRNAs (miR-185-5p, miR-223-3p and miR-3529-3p) inversely correlated with HIF-2α expression and associated with tumor shrinkage and PFS upon treatment with VEGFR-TKIs. These three miRNAs can have a predictive value not only upon treatment with VEGFR-TKIs but possibly also upon treatment with the upcoming HIF-2α inhibitor belzutifan.

4 May 2021 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SJS. C. Joosten
S. C. Joosten
SOS. N. O. Odeh
S. N. O. Odeh
AKA. Koch
A. Koch
NBN. Buekers
N. Buekers
MAM. J. B. Aarts
M. J. B. Aarts
KSKim Smits
Kim Smits
Background: Current risk models for renal cell carcinoma (RCC) based on clinicopathological factors are sub-optimal in accurately identifying high-risk patients. Here, we perform a head-to-head comparison of previously published DNA methylation markers and propose a potential prognostic model for clear cell RCC (ccRCC). Patients and methods: Promoter methylation of PCDH8, BNC1, SCUBE3, GREM1, LAD1, NEFH, RASSF1A, GATA5, SFRP1, CDO1, and NEURL was determined by nested methylation-specific PCR. To identify clinically relevant methylated regions, The Cancer Genome Atlas (TCGA) was used to guide primer design. Formalin-fixed paraffin-embedded (FFPE) tissue samples from 336 non-metastatic ccRCC patients from the prospective Netherlands Cohort Study (NLCS) were used to develop a Cox proportional hazards model using stepwise backward elimination and bootstrapping to correct for optimism. For validation purposes, FFPE ccRCC tissue of 64 patients from the University Hospitals Leuven and a series of 232 cases from The Cancer Genome Atlas (TCGA) were used. Results: Methylation of GREM1, GATA5, LAD1, NEFH, NEURL, and SFRP1 was associated with poor ccRCC-specific survival, independent of age, sex, tumor size, TNM stage or tumor grade. Moreover, the association between GREM1, NEFH, and NEURL methylation and outcome was shown to be dependent on the genomic region. A prognostic biomarker model containing GREM1, GATA5, LAD1, NEFH and NEURL methylation in combination with clinicopathological characteristics, performed better compared to the model with clinicopathological characteristics only (clinical model), in both the NLCS and the validation population with a c-statistic of 0.71 versus 0.65 and a c-statistic of 0.95 versus 0.86 consecutively. However, the biomarker model had limited added prognostic value in the TCGA series with a c-statistic of 0.76 versus 0.75 for the clinical model. Conclusion: In this study we performed a head-to-head comparison of potential prognostic methylation markers for ccRCC using a novel approach to guide primers design which utilizes the optimal location for measuring DNA methylation. Using this approach, we identified five methylation markers that potentially show prognostic value in addition to currently known clinicopathological factors.

30 May 2020 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
GSGreet Van De Sijpe
Greet Van De Sijpe
BBBenoit Beuselinck
Benoit Beuselinck
TNTine Van Nieuwenhuyse
Tine Van Nieuwenhuyse
RPRoxanne Poncelet
Roxanne Poncelet
OBOliver Bechter
Oliver Bechter
ISIsabel Spriet
Isabel Spriet

13 September 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
NBNiloefar Ahmadi Bidakhvidi
Niloefar Ahmadi Bidakhvidi
TGThomas Gevaert
Thomas Gevaert
MSMaxim De Schepper
Maxim De Schepper
MBMarcella Baldewijns
Marcella Baldewijns
EHEnrique Havinga
Enrique Havinga
Karolien GoffinKarolien Goffin
Karolien Goffin

9 February 2024 in Placenta
Verified
Journal Article
Closed access
GZGitte Zels
Gitte Zels
CCCecile Colpaert
Cecile Colpaert
DLDorien Leenaerts
Dorien Leenaerts
HNHeleen Nailis
Heleen Nailis
MVMagali Verheecke
Magali Verheecke
MBMarcella Baldewijns
Marcella Baldewijns